ArticleToxicology reports2025
Interpreting nirtetralin's anticancer efficacy in oral squamous cell carcinoma: Integrating experimental and computational perspectives.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protective Effect of a Polyherbal Formulation (Cardojith) Against Angiotensin II-induced Hypertension and Cardiomyocyte Hypertrophy Via Modulation of Oxidative Stress and MAPK Signalling.Applied biochemistry and biotechnology · 2026Article
- Fluorescence-Guided Chitosan and Eugenol-Based Carbon Dots for Comprehensive Infection Control and In Vitro Wound-Healing Applications in Dentistry.Dentistry journal · 2026Article
- Chloroquine as a potential anticancer agent for triple-negative breast cancer: effects on MDA-MB-231 cells.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cancer, particularly oral squamous cell carcinoma (OSCC), poses a formidable challenge in global health, urging the quest for innovative therapeutic interventions. Our study delved into exploring the anticancer efficacy of nirtetralin against OSCC cells, focusing keenly on deciphering its mode of action and pharmacokinetic attributes. Employing the MTT assay, we discerned a discernible, time-dependent suppression of KB cells with escalating doses of nirtetralin. Immunofluorescence staining by DCF-DA denotes the ROS production by treating nirtetralin in KB cells. To unravel the intricate molecular mechanisms at play, we turned to reverse transcription-polymerase chain reaction (RT-PCR) to scrutinize the gene interactions modulated by nirtetralin exposure. Our investigations unveiled noteworthy shifts in the expression patterns of epithelial-mesenchymal transition (EMT) markers, hinting at nirtetralin's potential in impeding EMT progression in oral cancer cells. Furthermore, leveraging molecular docking simulations, we unearthed strong binding affinities between nirtetralin and EMT targets, furnishing invaluable structural insights into its anticancer prowess. In tandem, employing the SWISS-ADME computational tool afforded a glimpse into the favourable pharmacokinetic attributes of nirtetralin, underscoring its promise as a viable therapeutic contender for oral cancer management. Cumulatively, our findings illuminate the multifaceted anticancer mechanisms orchestrated by nirtetralin against oral cancer, advocating its candidacy as a promising therapeutic avenue in combatting this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.